CT-868 is under clinical development by Carmot Therapeutics and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CT-868’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CT-868 overview

CT-868 is under development for the treatment of type-2 diabetes, obesity, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). The drug candidate is administered though subcutaneous route. The drug candidate acts by targeting the incretin hormones-glucagon like peptide1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide/Gastric inhibitory polypeptide receptor (GIP-R). The drug candidate is based on chemotype evolution technology.

Carmot Therapeutics overview

Carmot Therapeutics is a pharmaceutical and healthcare company. Its products include KRAS, MYC, Deubiquitinating Enzymes, GLP-1R and GIPR Dual Agonists. The company that discovers and develops drugs for the treatment of cancer, inflammation and metabolic diseases. It offers products such as protein-protein interactions NEMO and IKK for the treatment of cancer and inflammation; and GLP-1R and GIPR for treating Type 2 diabetes and obesity, among others. The company’s KRA product carters service to colorectal, lung and pancreatic cancers. Carmot Therapeutics is headquartered in Berkeley, California, the US.

For a complete picture of CT-868’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.